S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:GBIO

Generation Bio (GBIO) Stock Price, News & Analysis

$3.70
+0.53 (+16.72%)
(As of 03/27/2024 ET)
Today's Range
$3.23
$3.73
50-Day Range
$1.73
$3.70
52-Week Range
$0.86
$6.98
Volume
335,417 shs
Average Volume
278,159 shs
Market Capitalization
$245.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Generation Bio MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
116.2% Upside
$8.00 Price Target
Short Interest
Healthy
2.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.44mentions of Generation Bio in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$3,961 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.41) to ($1.01) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.91 out of 5 stars

Medical Sector

361st out of 939 stocks

Pharmaceutical Preparations Industry

164th out of 422 stocks

GBIO stock logo

About Generation Bio Stock (NASDAQ:GBIO)

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

GBIO Stock Price History

GBIO Stock News Headlines

GBIO May 2024 7.500 call
GBIO Apr 2024 5.000 call
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Generation Bio Co (GBIO)
Generation Z: Page 4
Charles Rowland Bought 179% More Shares In Generation Bio
JMP Securities Keeps Their Hold Rating on Generation Bio (GBIO)
See More Headlines
Receive GBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Generation Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/27/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GBIO
Fax
N/A
Employees
174
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$10.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+116.2%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-126,610,000.00
Pretax Margin
-2,144.51%

Debt

Sales & Book Value

Annual Sales
$5.90 million
Book Value
$3.07 per share

Miscellaneous

Free Float
52,650,000
Market Cap
$245.98 million
Optionable
Optionable
Beta
2.70
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Cameron Geoffrey McDonough M.D. (Age 54)
    President, CEO & Director
    Comp: $939.09k
  • Dr. Matthew Norkunas M.B.A. (Age 45)
    M.D., Chief Financial Officer
    Comp: $611.11k
  • Dr. Matthew Stanton Ph.D. (Age 50)
    Chief Scientific Officer
    Comp: $654.83k
  • Dr. Mark D. Angelino Ph.D. (Age 51)
    Co-Founder
  • Dr. Robert Kotin Ph.D. (Age 68)
    Co-Founder
  • Ms. Antoinette Paone M.B.A. (Age 45)
    M.S., Chief Operating Officer
  • Ms. Yalonda Howze J.D. (Age 51)
    Chief Legal Officer & Secretary
  • Ms. Jasmin Tower
    Chief Human Resources Officer
  • Dr. Phillip Samayoa Ph.D. (Age 36)
    Chief Strategy Officer

GBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Generation Bio stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Generation Bio in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GBIO, but not buy additional shares or sell existing shares.
View GBIO analyst ratings
or view top-rated stocks.

What is Generation Bio's stock price target for 2024?

6 brokerages have issued 12 month price objectives for Generation Bio's stock. Their GBIO share price targets range from $5.00 to $10.00. On average, they expect the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 116.2% from the stock's current price.
View analysts price targets for GBIO
or view top-rated stocks among Wall Street analysts.

How have GBIO shares performed in 2024?

Generation Bio's stock was trading at $1.65 at the beginning of 2024. Since then, GBIO stock has increased by 124.2% and is now trading at $3.70.
View the best growth stocks for 2024 here
.

Are investors shorting Generation Bio?

Generation Bio saw a drop in short interest in March. As of March 15th, there was short interest totaling 1,270,000 shares, a drop of 11.8% from the February 29th total of 1,440,000 shares. Based on an average trading volume of 327,000 shares, the days-to-cover ratio is currently 3.9 days. Currently, 2.6% of the shares of the stock are sold short.
View Generation Bio's Short Interest
.

When is Generation Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our GBIO earnings forecast
.

How were Generation Bio's earnings last quarter?

Generation Bio Co. (NASDAQ:GBIO) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by $0.02.

What other stocks do shareholders of Generation Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Generation Bio investors own include DocuSign (DOCU), NVIDIA (NVDA), Overstock.com (OSTK), Boeing (BA), Pure Storage (PSTG), Mastercard (MA), QUALCOMM (QCOM), Riot Platforms (RIOT), Twilio (TWLO) and Enphase Energy (ENPH).

When did Generation Bio IPO?

Generation Bio (GBIO) raised $126 million in an initial public offering on Friday, June 12th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Generation Bio's major shareholders?

Generation Bio's stock is owned by many different retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (10.48%), Price T Rowe Associates Inc. MD (10.48%), Vanguard Group Inc. (3.86%), Vanguard Group Inc. (3.84%), PFM Health Sciences LP (2.46%) and Goldman Sachs Group Inc. (1.75%). Insiders that own company stock include Antoinette Paone, Charles A Rowland Jr, Dannielle Appelhans, Donald William Nicholson, Douglas Kerr, Evan Spiegel, Geoff Mcdonough, Jason P Rhodes, Matthew Stanton, Phillip Samayoa and Venture Associates X L Atlas.
View institutional ownership trends
.

How do I buy shares of Generation Bio?

Shares of GBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GBIO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners